EFG International’s Myriad Genetics MYGN Stock Holding History

EFG International’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,983	Closed	-$94.4K	–	1120
2026 Q1	$94.4K	Hold	20,983	–	–	﹤0.01%	646
2025 Q4	$129K	Buy	+20,983	New	+$152K	﹤0.01%	593

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EFG International's MYGN Position: Q2 2026 in Review

EFG International sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 20,983 shares — an estimated $94.4K sold.

EFG International first reported a position in MYGN in Q4 2025 and held it in 2 quarters. The position peaked at $129K in Q4 2025. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

EFG International reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
EFG International sold 20,983 Myriad Genetics shares in Q2 2026, an estimated $94.4K.
EFG International first reported a position in Myriad Genetics in Q4 2025 and held it in 2 quarters.
EFG International's Myriad Genetics position peaked at $129K in Q4 2025.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on EFG International's 13F filing for Q2 2026, filed 14 Aug 2026.